Assessing the role of Chemokine (C-C motif) ligand 14 in AKI: a European consensus meeting

Background: Urinary Chemokine (C-C motif) ligand 14 (CCL14) is a biomarker associated with persistent severe acute kidney injury (AKI). There is limited data to support the implementation of this AKI biomarker to guide therapeutic actions. Methods: Sixteen AKI experts with clinical CCL14 experience...

Descripción completa

Detalles Bibliográficos
Autores: Koyner, JL, Arndt, C, de Irujo, JBM, Coelho, S, de la Peña, MGM, di Girolamo, L, Joannidis, M, Jorge-Monjas, P, Koch, C, Lobaz, S, Meyer, A, Ostermann, M, Pertica, N, Prowle, JR, Silversides, J, Zarbock, A, Echeverri, J, Harenski, K, Forni, LG
Tipo de recurso: artículo
Estado:Versión publicada
Fecha de publicación:2024
País:España
Institución:Institut d’Investigació Biomèdica Sant Pau (IIB Sant Pau)
Repositorio:r-IIB SANT PAU. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica Sant Pau
OAI Identifier:oai:iibsantpau.fundanetsuite.com:p18792
Acceso en línea:https://iibsantpau.fundanetsuite.com/Publicaciones/ProdCientif/PublicacionFrw.aspx?id=18792
http://ddd.uab.cat/record/310400
Access Level:acceso abierto
Palabra clave:Biomarker testing experience
C-C motif chemokine ligand 14 (CCL14)
consensus
critical care nephrology
persistent acute kidney injury
id ES_09e2d58f52b3ac957f6ffeb5907bbb9a
oai_identifier_str oai:iibsantpau.fundanetsuite.com:p18792
network_acronym_str ES
network_name_str España
repository_id_str
spelling Assessing the role of Chemokine (C-C motif) ligand 14 in AKI: a European consensus meetingKoyner, JLArndt, Cde Irujo, JBMCoelho, Sde la Peña, MGMdi Girolamo, LJoannidis, MJorge-Monjas, PKoch, CLobaz, SMeyer, AOstermann, MPertica, NProwle, JRSilversides, JZarbock, AEcheverri, JHarenski, KForni, LGBiomarker testing experienceC-C motif chemokine ligand 14 (CCL14)consensuscritical care nephrologypersistent acute kidney injuryBackground: Urinary Chemokine (C-C motif) ligand 14 (CCL14) is a biomarker associated with persistent severe acute kidney injury (AKI). There is limited data to support the implementation of this AKI biomarker to guide therapeutic actions. Methods: Sixteen AKI experts with clinical CCL14 experience participated in a Delphi-based method to reach consensus on when and how to potentially use CCL14. Consensus was defined as >= 80% agreement (participants answered with 'Yes', or three to four points on a five-point Likert Scale). Results: Key consensus areas for CCL14 test implementation were: identifying challenges and mitigations, developing a comprehensive protocol and pairing it with a treatment plan, and defining the target population. The majority agreed that CCL14 results can help to prioritize AKI management decisions. CCL14 levels above the high cutoff (> 13 ng/mL) significantly changed the level of concern for modifying the AKI treatment plan (p < 0.001). The highest level of concern to modify the treatment plan was for discussions on renal replacement therapy (RRT) initiation for CCL14 levels > 13 ng/mL. The level of concern for discussion on RRT initiation between High and Low, and between Medium and Low CCL14 levels, showed significant differences. Conclusion: Real world urinary CCL14 use appears to provide improved care options to patients at risk for persistent severe AKI. Experts believe there is a role for CCL14 in AKI management and it may potentially reduce AKI-disease burden. There is, however, an urgent need for evidence on treatment decisions and adjustments based on CCL14 results.TAYLOR & FRANCIS LTD2024info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionhttps://iibsantpau.fundanetsuite.com/Publicaciones/ProdCientif/PublicacionFrw.aspx?id=18792http://ddd.uab.cat/record/310400RENAL FAILUREISSN: 0886022XISSNe: 15256049reponame:r-IIB SANT PAU. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica Sant Pauinstname:Institut d’Investigació Biomèdica Sant Pau (IIB Sant Pau)Inglésinfo:eu-repo/semantics/openAccessoai:iibsantpau.fundanetsuite.com:p187922026-06-14T12:41:47Z
dc.title.none.fl_str_mv Assessing the role of Chemokine (C-C motif) ligand 14 in AKI: a European consensus meeting
title Assessing the role of Chemokine (C-C motif) ligand 14 in AKI: a European consensus meeting
spellingShingle Assessing the role of Chemokine (C-C motif) ligand 14 in AKI: a European consensus meeting
Koyner, JL
Biomarker testing experience
C-C motif chemokine ligand 14 (CCL14)
consensus
critical care nephrology
persistent acute kidney injury
title_short Assessing the role of Chemokine (C-C motif) ligand 14 in AKI: a European consensus meeting
title_full Assessing the role of Chemokine (C-C motif) ligand 14 in AKI: a European consensus meeting
title_fullStr Assessing the role of Chemokine (C-C motif) ligand 14 in AKI: a European consensus meeting
title_full_unstemmed Assessing the role of Chemokine (C-C motif) ligand 14 in AKI: a European consensus meeting
title_sort Assessing the role of Chemokine (C-C motif) ligand 14 in AKI: a European consensus meeting
dc.creator.none.fl_str_mv Koyner, JL
Arndt, C
de Irujo, JBM
Coelho, S
de la Peña, MGM
di Girolamo, L
Joannidis, M
Jorge-Monjas, P
Koch, C
Lobaz, S
Meyer, A
Ostermann, M
Pertica, N
Prowle, JR
Silversides, J
Zarbock, A
Echeverri, J
Harenski, K
Forni, LG
author Koyner, JL
author_facet Koyner, JL
Arndt, C
de Irujo, JBM
Coelho, S
de la Peña, MGM
di Girolamo, L
Joannidis, M
Jorge-Monjas, P
Koch, C
Lobaz, S
Meyer, A
Ostermann, M
Pertica, N
Prowle, JR
Silversides, J
Zarbock, A
Echeverri, J
Harenski, K
Forni, LG
author_role author
author2 Arndt, C
de Irujo, JBM
Coelho, S
de la Peña, MGM
di Girolamo, L
Joannidis, M
Jorge-Monjas, P
Koch, C
Lobaz, S
Meyer, A
Ostermann, M
Pertica, N
Prowle, JR
Silversides, J
Zarbock, A
Echeverri, J
Harenski, K
Forni, LG
author2_role author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
dc.subject.none.fl_str_mv Biomarker testing experience
C-C motif chemokine ligand 14 (CCL14)
consensus
critical care nephrology
persistent acute kidney injury
topic Biomarker testing experience
C-C motif chemokine ligand 14 (CCL14)
consensus
critical care nephrology
persistent acute kidney injury
description Background: Urinary Chemokine (C-C motif) ligand 14 (CCL14) is a biomarker associated with persistent severe acute kidney injury (AKI). There is limited data to support the implementation of this AKI biomarker to guide therapeutic actions. Methods: Sixteen AKI experts with clinical CCL14 experience participated in a Delphi-based method to reach consensus on when and how to potentially use CCL14. Consensus was defined as >= 80% agreement (participants answered with 'Yes', or three to four points on a five-point Likert Scale). Results: Key consensus areas for CCL14 test implementation were: identifying challenges and mitigations, developing a comprehensive protocol and pairing it with a treatment plan, and defining the target population. The majority agreed that CCL14 results can help to prioritize AKI management decisions. CCL14 levels above the high cutoff (> 13 ng/mL) significantly changed the level of concern for modifying the AKI treatment plan (p < 0.001). The highest level of concern to modify the treatment plan was for discussions on renal replacement therapy (RRT) initiation for CCL14 levels > 13 ng/mL. The level of concern for discussion on RRT initiation between High and Low, and between Medium and Low CCL14 levels, showed significant differences. Conclusion: Real world urinary CCL14 use appears to provide improved care options to patients at risk for persistent severe AKI. Experts believe there is a role for CCL14 in AKI management and it may potentially reduce AKI-disease burden. There is, however, an urgent need for evidence on treatment decisions and adjustments based on CCL14 results.
publishDate 2024
dc.date.none.fl_str_mv 2024
dc.type.none.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
format article
status_str publishedVersion
dc.identifier.none.fl_str_mv https://iibsantpau.fundanetsuite.com/Publicaciones/ProdCientif/PublicacionFrw.aspx?id=18792
http://ddd.uab.cat/record/310400
url https://iibsantpau.fundanetsuite.com/Publicaciones/ProdCientif/PublicacionFrw.aspx?id=18792
http://ddd.uab.cat/record/310400
dc.language.none.fl_str_mv Inglés
language_invalid_str_mv Inglés
dc.rights.none.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.publisher.none.fl_str_mv TAYLOR & FRANCIS LTD
publisher.none.fl_str_mv TAYLOR & FRANCIS LTD
dc.source.none.fl_str_mv RENAL FAILURE
ISSN: 0886022X
ISSNe: 15256049
reponame:r-IIB SANT PAU. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica Sant Pau
instname:Institut d’Investigació Biomèdica Sant Pau (IIB Sant Pau)
instname_str Institut d’Investigació Biomèdica Sant Pau (IIB Sant Pau)
reponame_str r-IIB SANT PAU. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica Sant Pau
collection r-IIB SANT PAU. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica Sant Pau
repository.name.fl_str_mv
repository.mail.fl_str_mv
_version_ 1869403132123938816
score 15,811543

Similares en LA Referencia